nach oben

Neurological Sciences

Erschienen in:

29.04.2020 | Original Article

MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy

verfasst von: Valentina Pegoraro, Paola Cudia, Alfonc Baba, Corrado Angelini

Erschienen in: Neurological Sciences | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

MiR-1 and myostatin are markers for muscle growth and regeneration. Myostatin has a key role in the regulation of muscle mass. Myotonic dystrophy type 1(DM1) patients have a disease-specific serum miRNA profile characterized by upregulation of miR-1, miR-206, miR-133a, and miR-133b (myomiRNAs).

This study aims to evaluate the possible utility of myomiRs and myostatin as biomarkers of rehabilitation efficacy in DM1, supporting clinical outcomes that are often variable and related to the patient’s clinical condition.

In 9 genetically proven DM1 patients, we collected biological samples before (T0) and after (T1) exercise rehabilitation training as biological measurement. We measured serum myomiRNAs by qRT-PCR and myostatin by ELISA test. The clinical outcomes measures that we utilized during a 3–6 week rehabilitation controlled aerobic exercise period were the 6-min walking test (6MWT) that increased significantly of 53.5 m (p < 0.0004) and the 10-m walk test (10MWT) that decreased of 1.38 s.

We observed, after physical rehabilitation, a significant downregulation of myomiRNAs and myostatin that occurred in parallel with the improvement of clinical functional outcome measures assessed as endurance and gait speed, respectively.

The modulation of biomarkers may reflect muscle regeneration and increase muscle mass after aerobic exercise. miRNAs and myostatin might be considered as circulating biomarkers of DM1 rehabilitation. The efficacy of physical rehabilitation in counteracting molecular pathways responsible for muscle atrophy and disease progression and the role of these biomarkers in DM1 and other neuromuscular diseases warrant further investigation.

Nur mit Berechtigung zugänglich

Gutiérrez Gutiérrez G, Díaz-Manera J, Almendrote M, Azriel S, Eulalio Bárcena J, Cabezudo García P, Camacho Salas A, Casanova Rodríguez C, Cobo AM, Díaz Guardiola P, Fernández-Torrón R, Gallano Petit MP, García Pavía P, Gómez Gallego M, Gutiérrez Martínez AJ, Jericó I, Kapetanovic García S, López de Munaín Arregui A, Martorell L, Morís de la Tassa G, Moreno Zabaleta R, Muñoz-Blanco JL, Olivar Roldán J, Pascual Pascual SI, Peinado Peinado R, Pérez H, Poza Aldea JJ, Rabasa M, Ramos A, Rosado Bartolomé A, Rubio Pérez MÁ, Urtizberea JA, Zapata-Wainberg G, Gutiérrez-Rivas E (2019) Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert’s disease. Med Clin 153:82.e1–82.e17. https://doi.org/10.1016/j.medcli.2018.10.028CrossRef

LoRusso S, Weiner B, Arnold WD (2018) Myotonic dystrophies: targeting therapies for multisystem disease. Neurotherapeutics 15:872–884. https://doi.org/10.1007/s13311-018-00679-zCrossRefPubMedPubMedCentral

Mignarri A, Gentili F, Masia F, Genua A, Cenciarelli S, Brunori P, Mazzei MA, Malandrini A, Federico A, Mazzei FG, Dotti MT (2018) Imaging of the thymus in myotonic dystrophy type 1. Neurol Sci 39:347–351. https://doi.org/10.1007/s10072-017-3202-4CrossRefPubMed

Sarparanta J, Jonson PH, Golzio C, Sandell S, Luque H, Screen M, McDonald K, Stajich JM, Mahjneh I, Vihola A, Raheem O, Penttilä S, Lehtinen S, Huovinen S, Palmio J, Tasca G, Ricci E, Hackman P, Hauser M, Katsanis N, Udd B (2012) Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 44(450–5):S1–S2. https://doi.org/10.1038/ng.1103CrossRef

Formaggio E, Del Felice A, Turco C et al (2018) Neurophysiological evidence of motor network reorganization in myotonic dystrophy type 1. J Clin Neurophysiol 36:1–81. https://doi.org/10.1097/WNP.0000000000000508CrossRef

Savić Pavićević D, Miladinović J, Brkušanin M, et al (2013) Molecular genetics and genetic testing in myotonic dystrophy type 1. BioMed Research international 2013:. https://doi.org/10.1155/2013/391821

Furling D (2012) Misregulation of alternative splicing and microRNA processing in DM1 pathogenesis. Rinshō shinkeigaku = Clinical neurology 52:1018–22

Mahadevan MS (2012) Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr Opin Neurol 25:609–613CrossRefPubMedPubMedCentral

Wang Y, Hao L, Li H, Cleary JD, Tomac MP, Thapa A, Guo X, Zeng D, Wang H, McRae MK, Jastrzemski O, Smith-Fassler AM, Xu Y, Xia G (2019) Abnormal nuclear aggregation and myotube degeneration in myotonic dystrophy type 1. Neurol Sci 40:1255–1265. https://doi.org/10.1007/s10072-019-03783-wCrossRefPubMed

10.

Gourdon G, Meola G (2017) Myotonic dystrophies: state of the art of new therapeutic developments for the CNS. Front Cell Neurosci 11:1–14. https://doi.org/10.3389/fncel.2017.00101CrossRef

11.

Pettersson OJ, Aagaard L, Jensen TG, Damgaard CK (2015) Molecular mechanisms in DM1 - a focus on foci. Nucleic Acids Res 43:2433–2441. https://doi.org/10.1093/nar/gkv029CrossRefPubMedPubMedCentral

12.

Park J-S, Kim N, Park D (2018) Diastolic heart dysfunction is correlated with CTG repeat length in myotonic dystrophy type 1. Neurol Sci 39:1935–1943. https://doi.org/10.1007/s10072-018-3530-zCrossRefPubMed

13.

Pegoraro V, Merico A, Angelini C (2019) MyomiRNAs Dysregulation in ALS rehabilitation. https://doi.org/10.3390/brainsci9010008

14.

Zhang S, Chen N (2018) Regulatory role of MicroRNAs in muscle atrophy during exercise intervention. International journal of molecular sciences 19:. https://doi.org/10.3390/ijms19020405

15.

Polakovičová M, Musil P, Laczo E, et al (2016) Circulating MicroRNAs as potential biomarkers of exercise response. International journal of molecular sciences 17:. https://doi.org/10.3390/ijms17101553

16.

Siracusa J, Koulmann N, Banzet S (2017) Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle 9:20–27. https://doi.org/10.1002/jcsm.12227CrossRefPubMedPubMedCentral

17.

Zhu H, Fan G-C (2011) Extracellular/circulating microRNAs and their potential role in cardiovascular disease. American journal of cardiovascular disease 1:138–149. https://doi.org/10.1016/j.biotechadv.2011.08.021.SecretedCrossRefPubMedPubMedCentral

18.

Mitchelson KR, Qin W-Y (2015) Roles of the canonical myomiRs miR-1, −133 and −206 in cell development and disease. World J Biol Chem 6:162–208. https://doi.org/10.4331/wjbc.v6.i3.162CrossRefPubMedPubMedCentral

19.

Tasca E, Pegoraro V, Merico A, Angelini C (2016) Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin Neuropathol 35:22–30. https://doi.org/10.5414/NP300889CrossRefPubMed

20.

Cacchiarelli D, Legnini I, Martone J, Cazzella V, D'Amico A, Bertini E, Bozzoni I (2011) miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine 3:258–265. https://doi.org/10.1002/emmm.201100133CrossRefPubMedPubMedCentral

21.

Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ, Phylactou LA (2015) Elevated muscle-specific miRNAs in serum of myotonic dystrophy patients relate to muscle disease progress. PLoS One 10:e0125341. https://doi.org/10.1371/journal.pone.0125341CrossRefPubMedPubMedCentral

22.

Fritegotto C, Ferrati C, Pegoraro V, Angelini C (2017) Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. Neurol Sci 38:619–625. https://doi.org/10.1007/s10072-017-2811-2CrossRefPubMed

23.

Falcone G, Perfetti A, Cardinali B, Martelli F (2014) Noncoding RNAs: emerging players in muscular dystrophies. Biomed Res Int 2014, 2014, 1, 12

24.

Makarova JA, Shkurnikov MU, Wicklein D, Lange T, Samatov TR, Turchinovich AA, Tonevitsky AG (2016) Intracellular and extracellular microRNA: an update on localization and biological role. Prog Histochem Cytochem 51:33–49. https://doi.org/10.1016/j.proghi.2016.06.001CrossRefPubMed

25.

Hitachi K, Tsuchida K (2014) Role of microRNAs in skeletal muscle hypertrophy. Front Physiol 4:408. https://doi.org/10.3389/fphys.2013.00408CrossRefPubMedPubMedCentral

26.

Horak M, Novak J, Bienertova-Vasku J (2016) Muscle-specific microRNAs in skeletal muscle development. Dev Biol 410:1–13. https://doi.org/10.1016/j.ydbio.2015.12.013CrossRefPubMed

27.

Alexander MS, Kunkel LM, Cell S, Children B (2015) Skeletal muscle MicroRNAs : their diagnostic and therapeutic potential in human muscle diseases. Journal of Neuromuscular Diseases 2:1–11. https://doi.org/10.3233/JND-140058CrossRefPubMedPubMedCentral

28.

Alton E, Inyoul L, Leroy H et al (2011) Extracellular microRNA: a new source of biomarkers. Mutat Res 717(1–2):85–90. https://doi.org/10.1016/j.mrfmmm.2011.03.004CrossRef

29.

Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda SI, Hashido K (2014) Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med 19:452–458. https://doi.org/10.1007/s12199-014-0405-7CrossRefPubMedPubMedCentral

30.

Perfetti A, Greco S, Cardani R, Fossati B, Cuomo G, Valaperta R, Ambrogi F, Cortese A, Botta A, Mignarri A, Santoro M, Gaetano C, Costa E, Dotti MT, Silvestri G, Massa R, Meola G, Martelli F (2016) Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. Sci Rep 6. https://doi.org/10.1038/srep38174

31.

Elliott B, Renshaw D, Getting S, Mackenzie R (2012) The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol 205:324–340. https://doi.org/10.1111/j.1748-1716.2012.02423.xCrossRef

32.

Hittel DS, Axelson M, Sarna N et al (2010) Myostatin decrease with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 42:2023–2029. https://doi.org/10.1249/MSS.0b013e3181e0b9a8.MyostatinCrossRefPubMedPubMedCentral

33.

Delanaye P, Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski JM, Pottel H, Burtey S, Bruyère O, Cavalier E (2019) Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 29:511–520. https://doi.org/10.1053/j.jrn.2018.11.010CrossRef

34.

Cudia P, Weis L, Baba A, Kiper P, Marcante A, Rossi S, Angelini C, Piccione F (2016) Effects of functional electrical stimulation lower extremity training in myotonic dystrophy type I: a pilot controlled study. Am J Phys Med Rehabil 95:809–817. https://doi.org/10.1097/PHM.0000000000000497CrossRefPubMed

35.

Kierkegaard M, Tollbäck A (2007) Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord 17:943–949. https://doi.org/10.1016/j.nmd.2007.08.003CrossRefPubMed

36.

Freischmidt A, Müller K, Zondler L, Weydt P, Volk AE, Božič AL, Walter M, Bonin M, Mayer B, von Arnim CAF, Otto M, Dieterich C, Holzmann K, Andersen PM, Ludolph AC, Danzer KM, Weishaupt JH (2014) Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 137:2938–2950. https://doi.org/10.1093/brain/awu249CrossRefPubMed

37.

Logigian EL, Martens WB, Moxley RT, McDermott MP, Dilek N, Wiegner AW, Pearson AT, Barbieri CA, Annis CL, Thornton CA, Moxley RT (2010) Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 74:1441–1448. https://doi.org/10.1212/WNL.0b013e3181dc1a3aCrossRefPubMedPubMedCentral

38.

Voet BMN, van der Kooi EL, Riphagen II et al (2013) Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003907.pub4.www.cochranelibrary.com

39.

Roussel M-P, Morin M, Gagnon C, Duchesne E (2019) What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. BMC Musculoskelet Disord 20:101. https://doi.org/10.1186/s12891-019-2458-7CrossRefPubMedPubMedCentral

40.

Siciliano G, Simoncini C, Giannotti S, Zampa V, Angelini C, Ricci G (2015) Muscle exercise in limb girdle muscular dystrophies: pitfall and advantages. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 34:3–8

41.

Baldanzi S, Ricci G, Bottari M, Chico L, Simoncini C, Siciliano G (2017) The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1. Arch Ital Biol 155:43–53. https://doi.org/10.12871/000398292017125CrossRefPubMed

42.

Nielsen S, Scheele C, Yfanti C, Åkerström T, Nielsen AR, Pedersen BK, Laye M (2010) Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. J Physiol 588:4029–4037. https://doi.org/10.1113/jphysiol.2010.189860CrossRefPubMedPubMedCentral

43.

Russell AP, Lamon S, Boon H, Wada S, Güller I, Brown EL, Chibalin AV, Zierath JR, Snow RJ, Stepto N, Wadley GD, Akimoto T (2013) Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training. The Authors The Journal of Physiology C 591:4637–4653. https://doi.org/10.1113/jphysiol.2013.255695CrossRef

44.

Marinho R, Alcântara PSM, Ottoch JP, Seelaender M (2017) Role of exosomal microRNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Frontiers in nutrition 4:69. https://doi.org/10.3389/fnut.2017.00069CrossRefPubMed

45.

Kukreti H, Amuthavalli K, Harikumar A, et al (2013) Muscle-specific microRNA1 (miR1) targets heat shock protein 70 (HSP70) during dexamethasone-mediated atrophy. 288:6663–6678. https://doi.org/10.1074/jbc.M112.390369

46.

Perfetti A, Greco S, Bugiardini E, Cardani R, Gaia P, Gaetano C, Meola G, Martelli F (2014) Plasma microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscul Disord 24:509–515. https://doi.org/10.1016/j.nmd.2014.02.005CrossRefPubMed

Titel: MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy
verfasst von: Valentina Pegoraro
Paola Cudia
Alfonc Baba
Corrado Angelini
Publikationsdatum: 29.04.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 10/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04409-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Pediatric anti-HMGCR necrotizing myopathy: diagnostic challenges and literature review

Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases

Theory of mind in Parkinson’s disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy

NGS-based detection of a novel mutation in PRKCG (SCA14) in sporadic adult-onset ataxia plus dystonic tremor

Comment on “Increased Epicardial Fat Thickness and Carotid Intima–Media Thickness in Migraine Patients”

Impact of COVID-19 on neurological manifestations: an overview of stroke presentation in pandemic

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie